Thursday, November 19, 2015 3:42:06 PM
MNOV is attempting to treat just about everything with its drugs. I have never seen any company of this size with so many irons in the fire. And they have been able to fund their trials with external sources of money.
MNOV's chart is improving. However it will take news that confirms that their drugs work in one of these research projects for a big move to take place. The market cap is about $97m so there is plenty of possible room to the upside if good news is revealed.
Kind regards,
Minding
-----------------
MediciNova initiates mid-stage study of MN-001 for elevated triglycerides in NASH patients
Nov 19 2015, 12:05 ET | By: Douglas W. House, SA News Editor Contact this editor with comments or a news tip
MediciNova (MNOV -1.9%) initiates a Phase 2a clinical trial assessing MN-001 (tipelukast) for the treatment of hypertriglyceridemia in NASH (nonalcoholic steatohepatitis) patients. The open-label, multicenter, proof-of-concept study will enroll ~20 participants. Eligible patients will have a confirmed diagnosis of NASH and serum triglyceride levels of at least 150 mg/dL (normal level is less than 150 mg/dL). Each subject will receive 250 mg of MN-001 once per day for four weeks followed by 250 mg twice per day for eight weeks.
MN-001 is under development for the treatment of NASH with fibrosis and ideopathic pulmonary fibrosis.
Tipelukast is a small molecule anti-fibrotic and anti-inflammatory compound that exerts its effects via several mechanisms, including leukotriene receptor antagonism and inhibiting enzymes known as phosphodiesterases as well as 5-lipoxygenase.
Previously: MediciNova's tipelukast Fast Track'd for ideopathic pulmonary fibrosis; shares up 17% premarket (Sept. 10)
Previously: MediciNova jumps on FDA OK of second Phase 2 protocol for MN-001 in NASH (July 27)
MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan
MNOV: Presentation on ALS Phase 2 Study in December?
FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis
MediciNova Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled in Phase 2 Clinical Trial of MN-166 (ibudilast)
MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence
MediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis
Recent MNOV News
- MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND • GlobeNewswire Inc. • 09/09/2024 11:00:00 PM
- MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting • GlobeNewswire Inc. • 09/03/2024 11:00:00 PM
- MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition • GlobeNewswire Inc. • 08/29/2024 11:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:32:00 PM
- MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations • GlobeNewswire Inc. • 06/20/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 11:41:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 11:40:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 11:40:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:15:10 PM
- MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer • GlobeNewswire Inc. • 06/05/2024 10:00:00 AM
- MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 • GlobeNewswire Inc. • 06/03/2024 10:00:00 AM
- MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions • GlobeNewswire Inc. • 05/28/2024 10:00:00 AM
- MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer • GlobeNewswire Inc. • 05/20/2024 10:00:00 AM
- MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome • GlobeNewswire Inc. • 05/14/2024 10:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:15:29 PM
- MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) • GlobeNewswire Inc. • 05/07/2024 10:00:00 AM
- MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) • GlobeNewswire Inc. • 04/02/2024 11:00:00 PM
- MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan • GlobeNewswire Inc. • 03/26/2024 11:00:00 PM
- MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society • GlobeNewswire Inc. • 03/20/2024 11:00:00 PM
- MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology • GlobeNewswire Inc. • 03/12/2024 10:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/15/2024 09:25:31 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/19/2024 09:27:28 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/19/2024 09:25:25 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/19/2024 09:23:50 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/19/2024 09:21:57 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM